Oncology
The Current State of Liquid Biopsy in India
Perspectives from leading clinicians, laboratory scientists and diagnostics leaders on where liquid biopsy stands in India today.
Category
Ad board report
Region
India
Panel
11 KOLs across 9 institutions
Published
2026
About this ad board
An exclusive advisory board report bringing together perspectives from leading clinicians, laboratory scientists, and diagnostics leaders on where liquid biopsy stands in India today. Discover how adoption is unfolding in practice, what the journey from sample to report looks like, and the emerging opportunities that are shaping the next chapter of precision oncology.
Study questions
01What is the role of liquid biopsy in clinical practice today, and which analytes are most relied upon?
02Which cancer types and clinical scenarios see the highest adoption today, and where is growth expected to be fastest?
03What triggers a liquid biopsy test, and what does the sample journey from collection to report involve?
04What does a “negative” liquid biopsy result actually mean?
05How is the choice made between a targeted panel and comprehensive profiling, and has the lab-developed test model helped or hindered adoption?
06What is the typical turnaround time from blood collection to an actionable report, and where do delays occur?
07What are the biggest barriers to wider adoption of liquid biopsy in India?
08What is the outlook for multi-cancer early detection, and what India-specific evidence is still needed?
09Which emerging biomarkers beyond cfDNA hold the most promise?
10Where will artificial intelligence create the greatest value across the workflow?
11What policy and infrastructure investments would have the greatest impact on scaling liquid biopsy nationally?
12How do industry leaders expect liquid biopsy adoption in India to evolve over the next few years?
Precision diagnostics is evolving fast
Discover how we can help